Amend Pilot Program News Today

In American National Manufacturing Inc. v. Sleep Number Corporation, the Federal Circuit held that so long as a proposed claim amendment does not enlarge the scope of the claims...

The USPTO hosted a “Boardside Chat” on June 15, 2023, to discuss the Motion to Amend Pilot Program, including the recent call for public input on the PTAB’s existing claim amendment...

The USPTO hosted a "Boardside Chat" on June 15, 2023, to discuss the Motion to Amend Pilot Program, including the recent call for public input on the PTAB's existing claim amendment procedures and potential rule changes.

Companies subject to allegations of patent infringement have a strong interest in the outcome and review of post-grant patent challenges. Docket Navigator reports that the number of...

On October 4, 2022, the United States Patent and Trademark Office (USPTO) announced that it would be extending the Motion to Amend (MTA) Pilot Program at the Patent Trial and Appeal Board (PTAB)...

On October 4, 2022, the United States Patent and Trademark Office (USPTO) announced that it would be extending the Motion to Amend (MTA) Pilot Program at the Patent Trial and Appeal...

In Flex Logix Techs. Inc. v. Venkat Konda, PGR2019-00037, Paper 37 the Patent Trial and Appeal Board found the patent owner’s proposed amended claims unpatentable, in large part because the patent owner did not sufficiently respond to the Board’s preliminary guidance.     

No Unpatentability in a Successful Motion to Amend Tuesday, February 23, 2021 Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00712, Paper 112 (P.T.A.B. Oct. 22, 2019),  aff’d without opinion (Fed. Cir. Jan. 15, 2021), the Patent Trial and Appeal Board (“PTAB”) granted Patent Owner’s motion to amend, finding that Petitioner had not shown the proposed substitute claims to be unpatentable. Background The drug at issue was JEVTANA ® (cabazitaxel), which is indicated for use ...